Navigation Links
Study in Science holds promise for a new approach to drug therapy

Researchers believe they have found a way to change the action of 60 percent of currently available medications, in some cases making them many times more effective, according to an article published in the April 21 edition of the journal Science. The discovery has the potential to improve treatments for diseases including heart disease, cancer, diabetes, depression and arthritis. The study describes a new way to manipulate perhaps the most important signaling mechanism in human cells: G-protein coupled receptors (GPCRs).

Human cells must be able to send signals that switch life processes on and off as they react to the nutrients, toxins, hormones and even the light particles they are exposed to. GPCRs are a key part of such signaling cascades, passing on messages that make vision possible, carry nerve messages, enable white blood cells to attack infection and set the timing of the heartbeat. Faulty GPCR signaling, on the other hand, plays a key role in several major diseases. As a result, GCPRs are targeted by 12 of the top 20 selling drugs, including Coreg for congestive heart failure, Cozaar for high blood pressure, Zoladex for breast cancer, Buspar for anxiety and Clozaril for schizophrenia, as well as by Zantac and Claritin. Together the drug class accounts for $200 billion in annual sales.

Authors of the current study believe they have found a new way to regulate the same GCPR pathways, but at different points. Where most drugs change the behavior of GPCRs on the outside of cells, the new class of drugs seeks to influence related signaling on the inside. Early studies suggest that the newly discovered "drug candidates" can provide better control of pathways involved in pain relief, inflammation and heart disease, while leaving healthy functions in place.

"We believe we have discovered a new class of drugs that could make current drugs more effective, but that also represents a completely new, independent way of treating the same disease
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4 5

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Science holds promise for new approach drug therapy

(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... An organelle called the nucleolus resides deep within the ... critical functions: it manufactures ribosomes, the molecular machines that ... proteins that do the work of life. , ... Sciences Division of the Department of Energy's Lawrence Berkeley ...
... A solar-powered robot with 20/20 vision, on a search-and-destroy quest ... crop rows at the experimental fields at the University of ... weeds while significantly reducing herbicide use. , The robot uses ... on a frame on top of the machine to give ...
... Women infected with dormant toxoplasmosis are more likely to ... negative, according to research by S. Kankova and colleagues ... University; the Centre of Reproductive Medicine; and GynCentrum, in ... of the parasite Toxoplasma gondii in the mothers' blood, ...
Cached Biology News:Regulating the nuclear architecture of the cell 2Regulating the nuclear architecture of the cell 3Regulating the nuclear architecture of the cell 4Regulating the nuclear architecture of the cell 5New system could drastically reduce herbicide use 2New system could drastically reduce herbicide use 3Bad blood between boys and girls 2
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ... & USA BioSimilar Market Analysis to 2021" report ... Biosimilar market will be initiated in September as Sandoz ... the global market react? Will biosimilars explode into the ... the US economy up to $250 billion within the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased ... present a session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & ... largest analytical and scientific instruments show which will be held at International Conference ...
(Date:8/28/2015)... ... 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the ... service. Images such as the Fonz in a lab coat and Large Marge have ... humdrum spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer ...
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Neogen acquires U.K.-based Lab M Holdings 2
... JLL Partners, a leading private equity investment fund ("JLL") ... JLL PharmaNet Holdings, LLC ("Parent"), through its wholly-owned subsidiary, ... affiliate of JLL, has commenced a tender offer for ... ) at a price of $5.00 per share net ...
... Calif., Feb. 12 BioMarin Pharmaceutical,Inc. (Nasdaq: ... first interim efficacy,analysis (IEA) for the Riquent(R) Phase ... determined that the continuation of the trial is,futile. ... decided to stop the,study, unblind the data and ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... on bringing the life saving potential of stem cells ... that between January 1, 2009, and today, it has ... Company previously said in press releases and CEO interviews ...
Cached Biology Technology:An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 2An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 3An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 4An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 5An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 6An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share 7Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3Cord Blood Announces $1 Million Reduction in Long Term Debt 2
... is a microprocessor controlled, high speed ... with exceptionally smooth operation make the ... involving fluorescence microscopy, ratio imaging, spectrophotometry, ... rapid and accurate aperture positioning. The ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... a hydrolytic enzyme that catalyzes the ... glucose, maltose, maltotriose and,dextrins. The level ... the human,body are of clinical importance,1-3 ... enzymes for industry.4, The EnzChek Amylase ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
Biology Products: